Patients may require specific diagnostic, surveillance, and therapeutic management.
Thai Ho, MD, PhD
Advertisement
Dr. Ho is an associate professor of medicine in the Division of Hematology/Oncology, Department of Internal Medicine at Mayo Clinic, Phoenix, Arizona.
Articles by Thai Ho, MD, PhD
Combination therapy is the first-line standard for metastatic renal cell carcinoma.
Advertisement
Latest Updated Articles
Recognizing hereditary syndromes in renal cell carcinomaPublished: August 31st 2021 | Updated:
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5
